Global Post-traumatic Stress Disorder Treatment Market Size study, by Drug Class, by Demographics, by Distribution Channel and Regional Forecasts 2022-2032

Description

The global post-traumatic stress disorder (PTSD) treatment market was valued at USD 2.14 billion in 2023 and is anticipated to grow at a compound annual growth rate (CAGR) of 4.08% over the forecast period of 2024-2032. PTSD, a serious mental health condition triggered by traumatic experiences, continues to garner attention globally due to the growing awareness of its profound societal and economic impacts. With an increase in the prevalence of traumatic events, including wars, natural disasters, and incidents of sexual violence, the demand for effective PTSD therapies has surged.

The market has witnessed substantial growth propelled by an increasing focus on mental health awareness, government initiatives, and advancements in therapeutic solutions. Furthermore, the incorporation of novel technologies such as virtual reality therapy and precision medicine has revolutionized the PTSD treatment paradigm. These advancements facilitate tailored interventions, significantly improving patient outcomes. However, a limited range of FDA-approved medications continues to hinder broader treatment accessibility, underscoring the need for further innovation in this domain.

North America emerged as the leading regional market in 2023, accounting for a substantial share due to heightened awareness, robust healthcare infrastructure, and the prevalence of PTSD cases among veterans and survivors of severe trauma. Meanwhile, the Asia-Pacific region is anticipated to witness the fastest growth during the forecast period, supported by expanding healthcare investments and rising mental health awareness in emerging economies like India and China.

Major market players included in this report are:

1. AstraZeneca
2. Pfizer Inc.
3. GSK plc.
4. Otsuka Holdings Co., Ltd.
5. Jazz Pharmaceuticals, Inc.
6. Merck KGaA
7. Bionomics
8. Eli Lilly and Company
9. Viatris Inc.
10. Lupin
11. Aurobindo Pharma
12. Johnson & Johnson
13. Teva Pharmaceuticals
14. Boehringer Ingelheim
15. Lundbeck A/S

The detailed segments and sub-segment of the market are explained below:

By Drug Class:

Antidepressants
Anti-anxiety
Antipsychotics
Other Drug Class

By Demographics:

Adult
Children
Geriatric

By Distribution Channel:

Retail Pharmacies
Hospital Pharmacies
Other Pharmacies

By Region:

North America: U.S., Canada, Mexico
Europe: Germany, UK, France, Italy, Spain, Denmark, Sweden, Norway
Asia-Pacific: China, Japan, India, South Korea, Australia, Thailand
Latin America: Brazil, Argentina
Middle East & Africa: South Africa, Saudi Arabia, UAE, Kuwait

Years considered for the study are as follows:

Historical Year: 2022
Base Year: 2023
Forecast Period: 2024 to 2032

Key Takeaways:

Market estimates & forecast for 10 years from 2022 to 2032.
Annualized revenues and regional-level analysis for each market segment.
Detailed analysis of geographical landscapes with country-level analysis of major regions.
Competitive landscape information on major market players.
Analysis of key business strategies and recommendations on future market approaches.
Insights into demand-side and supply-side market dynamics.

Chapter 1. Global Post-traumatic Stress Disorder Treatment Market Executive Summary

1.1. Global PTSD Treatment Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Drug Class
- 1.3.2. By Demographics
- 1.3.3. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Post-traumatic Stress Disorder Treatment Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Post-traumatic Stress Disorder Treatment Market Dynamics

3.1. Market Drivers
- 3.1.1. Rising prevalence of trauma-inducing events
- 3.1.2. Increased awareness about mental health
- 3.1.3. Advances in therapeutic technologies
3.2. Market Challenges
- 3.2.1. Limited FDA-approved drugs
- 3.2.2. High costs of psychiatric treatments
3.3. Market Opportunities
- 3.3.1. Development of novel drug classes
- 3.3.2. Expanding healthcare access in emerging regions

Chapter 4. Global Post-traumatic Stress Disorder Treatment Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Post-traumatic Stress Disorder Treatment Market Size & Forecast by Drug Class (2022-2032)

5.1. Segment Dashboard
5.2. Global PTSD Treatment Market: Drug Class Revenue Trend Analysis (2022-2032)
- 5.2.1. Antidepressants
- 5.2.2. Anti-anxiety
- 5.2.3. Antipsychotics
- 5.2.4. Other Drug Class

Chapter 6. Global Post-traumatic Stress Disorder Treatment Market Size & Forecast by Demographics (2022-2032)

6.1. Segment Dashboard
6.2. Global PTSD Treatment Market: Demographics Revenue Trend Analysis (2022-2032)
- 6.2.1. Adult
- 6.2.2. Children
- 6.2.3. Geriatric

Chapter 7. Global Post-traumatic Stress Disorder Treatment Market Size & Forecast by Distribution Channel (2022-2032)

7.1. Segment Dashboard
7.2. Global PTSD Treatment Market: Distribution Channel Revenue Trend Analysis (2022-2032)
- 7.2.1. Retail Pharmacies
- 7.2.2. Hospital Pharmacies
- 7.2.3. Other Pharmacies

Chapter 8. Global Post-traumatic Stress Disorder Treatment Market Size & Forecast by Region (2022-2032)

8.1. North America
- 8.1.1. U.S.
- 8.1.2. Canada
- 8.1.3. Mexico
8.2. Europe
- 8.2.1. Germany
- 8.2.2. UK
- 8.2.3. France
- 8.2.4. Italy
- 8.2.5. Spain
- 8.2.6. Rest of Europe
8.3. Asia-Pacific
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. India
- 8.3.4. South Korea
- 8.3.5. Australia
- 8.3.6. Rest of Asia Pacific
8.4. Latin America
- 8.4.1. Brazil
- 8.4.2. Argentina
- 8.4.3. Rest of Latin America
8.5. Middle East & Africa (MEA)
- 8.5.1. South Africa
- 8.5.2. Saudi Arabia
- 8.5.3. UAE
- 8.5.4. Kuwait
- 8.5.5. Rest of MEA

Chapter 9. Competitive Intelligence

9.1. Key Company SWOT Analysis
- 9.1.1. AstraZeneca
- 9.1.2. Pfizer Inc.
- 9.1.3. GSK plc.
9.2. Top Market Strategies
9.3. Company Profiles
- 9.3.1. AstraZeneca
- 9.3.2. Pfizer Inc.
- 9.3.3. GSK plc.
- 9.3.4. Otsuka Holdings Co., Ltd
- 9.3.5. Jazz Pharmaceuticals, Inc.
- 9.3.6. Merck KGaA
- 9.3.7. Bionomics
- 9.3.8. Eli Lilly and Company
- 9.3.9. Viatris Inc.
- 9.3.10. Aurobindo Pharma

Chapter 10. Research Process

10.1. Data Mining
10.2. Analysis
10.3. Market Estimation
10.4. Validation
10.5. Publishing